NASDAQ: XAIRBeyond Air Inc Stock
$2.28-0.14 (-5.79%)
Updated Sep 17, 2025
XAIR Price
$2.28
Fair Value Price
N/A
Market Cap
$11.92M
52 Week Low
$2.02
52 Week High
$13.52
P/E
-0.2x
P/B
1.2x
P/S
3.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.78M
Earnings
-$42.12M
Gross Margin
-24.6%
Operating Margin
-826.24%
Profit Margin
-880.7%
Debt to Equity
1.78
Operating Cash Flow
-$33M
Beta
0.99
Next Earnings
Nov 17, 2025
Ex-Dividend
N/A
Next Dividend
N/A
XAIR Overview
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XAIR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important XAIR news, forecast changes, insider trades & much more!
XAIR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XAIR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XAIR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XAIR is good value based on its book value relative to its share price (1.2x), compared to the US Medical Devices industry average (3.98x)
P/B vs Industry Valuation
XAIR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XAIR due diligence checks available for Premium users.
Valuation
XAIR fair value
Fair Value of XAIR stock based on Discounted Cash Flow (DCF)
Price
$2.28
Fair Value
-$1.10
Undervalued by
308.00%
XAIR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XAIR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
30.71x
Market
37.36x
XAIR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.2x
Industry
3.98x
XAIR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XAIR's financial health
Profit margin
Revenue
$1.8M
Net Income
-$7.7M
Profit Margin
-437%
XAIR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XAIR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$28.1M
Liabilities
$17.7M
Debt to equity
1.78
XAIR's short-term assets ($14.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XAIR's short-term assets ($14.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XAIR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XAIR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
$576.0k
Financing
$4.1M
XAIR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XAIR vs Medical Device Stocks
Beyond Air Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.